Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue.
Prabhu L, Martin M, Chen L, Demir Ö, Jin J, Huang X, Motolani A, Sun M, Jiang G, Nakshatri H, Fishel ML, Sun S, Safa A, Amaro RE, Kelley MR, Liu Y, Zhang ZY, Lu T. Prabhu L, et al. Among authors: kelley mr. Genes Dis. 2022 Apr 13;10(1):267-283. doi: 10.1016/j.gendis.2022.04.001. eCollection 2023 Jan. Genes Dis. 2022. PMID: 37013054 Free PMC article.
In vitro and In vivo evidence demonstrating chronic absence of Ref-1 Cysteine 65 impacts Ref-1 folding configuration, redox signaling, proliferation and metastasis in pancreatic cancer.
Mijit M, Kpenu E, Chowdhury NN, Gampala S, Wireman R, Liu S, Babb O, Georgiadis MM, Wan J, Fishel ML, Kelley MR. Mijit M, et al. Among authors: kelley mr. Redox Biol. 2024 Feb;69:102977. doi: 10.1016/j.redox.2023.102977. Epub 2023 Dec 1. Redox Biol. 2024. PMID: 38056311 Free PMC article.
New Ref-1/APE1 targeted inhibitors demonstrating improved potency for clinical applications in multiple cancer types.
Gampala S, Moon HR, Wireman R, Peil J, Kiran S, Mitchell DK, Brewster K, Mang H, Masters A, Bach C, Smith-Kinnamen W, Doud EH, Rai R, Mosley AL, Quinney SK, Clapp DW, Hamdouchi C, Wikel J, Zhang C, Han B, Georgiadis MM, Kelley MR, Fishel ML. Gampala S, et al. Among authors: kelley mr. Pharmacol Res. 2024 Mar;201:107092. doi: 10.1016/j.phrs.2024.107092. Epub 2024 Feb 2. Pharmacol Res. 2024. PMID: 38311014 Free PMC article.
Ref-1 is overexpressed in neovascular eye disease and targetable with a novel inhibitor.
Muniyandi A, Hartman GD, Sishtla K, Rai R, Gomes C, Day K, Song Y, Masters AR, Quinney SK, Qi X, Woods H, Boulton ME, Meyer JS, Vilseck JZ, Georgiadis MM, Kelley MR, Corson TW. Muniyandi A, et al. Among authors: kelley mr. Angiogenesis. 2025 Jan 5;28(1):11. doi: 10.1007/s10456-024-09966-0. Angiogenesis. 2025. PMID: 39756006
APE1/Ref-1 as a Therapeutic Target for Inflammatory Bowel Disease.
Sahakian L, Robinson AM, Sahakian L, Stavely R, Kelley MR, Nurgali K. Sahakian L, et al. Among authors: kelley mr. Biomolecules. 2023 Oct 24;13(11):1569. doi: 10.3390/biom13111569. Biomolecules. 2023. PMID: 38002251 Free PMC article. Review.
251 results